-
Accelerating the pathway from drug discovery to patient treatment – pioneering advanced development methodologies for new TB drug regimens.
Read More.. -
Empowering African clinical trial sites through tailored local monitoring programmes.
Read More.. -
Developing limitless collaboration opportunities – academia, enterprises, governments, foundations, patient groups – a unique platform provided through a non-commercial broker!
Read More..
Pan-African Consortium for the Evaluation of Antituberculosis Antibiotics
We are faced with a global pandemic of tuberculosis and new tools to control this disease are needed urgently. We believe that new drugs are central to any control strategy and the fastest route to tuberculosis elimination.
The consortium brings together a group of scientists from more that 14 countries with skills in clinical trials, pulmonology, mycobacteriology, pharmacokinetics, statistics and delivery of clinical service.
Our Scientific Network
PanACEA in “World TB Day 2014 – Reach the 3 Million”
On March 24, 2014, Michael Hoelscher (LMU) presented “Advances in New TB Drug Development”, Tim McHugh (UCL) “Approaches to Monitoring Therapy” and Patrick Phillips...
MAMS STUDY: Enrolment is Now Completed
On March 24 (on World TB Day), the MAMS TB-01 Study has completed enrolment ahead of schedule! We congratulate and thank everybody in achieving this goal prior to the...
MAMS study has completed first interim analysis
PanACEA, the Pan-African Consortium for the Evaluation of Antituberculosis Antibiotics aims to develop TB regimens that significantly shorten treatment duration, funded...